{"id":"dual-integrin-antagonist","_chembl":{"chemblId":"CHEMBL4303227","moleculeType":"Small molecule","molecularWeight":"951.21"},"_dailymed":null,"mechanism":{"target":"Integrin receptors","explanation":"Integrins are transmembrane receptors that facilitate cellular adhesion and signal transduction. By antagonizing multiple integrin subtypes simultaneously, this dual-targeting approach may provide broader therapeutic effects in conditions where integrin-mediated pathways contribute to disease pathology.","oneSentence":"Blocks multiple integrin receptors to inhibit cell adhesion and signaling pathways involved in disease processes."},"_scrapedAt":"2026-03-28T03:11:24.656Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"_claudeStub":{"ts":1779122889,"model":"claude-sonnet-4-5-20250929"},"competitors":[{"name":"vedolizumab","brand":"Entyvio","company":"Takeda","rationale":"Integrin antagonist targeting α4β7 for inflammatory bowel disease"},{"name":"natalizumab","brand":"Tysabri","company":"Biogen","rationale":"Integrin antagonist targeting α4 integrin for multiple sclerosis"}],"description":"Dual Integrin Antagonist is an investigational therapy developed by Hoffmann-La Roche currently in Phase 2 clinical development. Integrins are cell surface receptors that mediate cell-cell and cell-extracellular matrix interactions, playing roles in inflammation, fibrosis, and cancer progression.","indications":{"approved":[{"status":"investigational","condition":null,"patientPopulation":null}]},"trialDetails":[{"nctId":"NCT00048022","phase":"PHASE2","title":"Inhaled Corticosteroid Replacement Study - Efficacy and Safety of Ro 27-2441 (Test Drug) in Moderate Persistent Asthma","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2002-10-25","conditions":"Asthma","enrollment":""},{"nctId":"NCT00048009","phase":"PHASE2","title":"Evaluation of Various Doses of Ro 27-2771 (Test Drug) in Asthmatic Patients Not Treated With Inhaled Corticosteroids","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2002-10-25","conditions":"Asthma","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":13,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Dual Integrin Antagonist","genericName":"Dual Integrin Antagonist","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A Dual Integrin Antagonist was studied in a clinical trial for the treatment of asthma. The trial, which was completed in 2007, evaluated the efficacy of the Dual Integrin Antagonist in patients with asthma not treated with inhaled corticosteroids.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}